Prevention & care

Prostate cancer: PSA, grade and stage, surveillance, treatment trade-offs, and long-term trial evidence

8 sources · Latest source check 2026-10-08 UTC

On this page

Prostate cancer starts in the prostate, a gland below the bladder that contributes fluid to semen. Anyone with a prostate can develop it. Some tumors grow slowly, while others are more aggressive; a single general survival statistic cannot describe every diagnosis.[1]

Symptoms, a blood marker and pathology answer different questions

Symptoms, a blood marker and pathology answer different questions
Finding	Meaning
Urinary symptoms	Can occur with cancer or noncancerous prostate problems.[2]
PSA result	Can prompt assessment; it does not establish cancer.[2]
Biopsy	Tissue is examined for cancer cells.[3]

Most prostate cancers are glandular cancers

NCI describes most primary prostate cancers as adenocarcinomas. Rarer tissue types exist and may behave differently. “Prostate cancer” alone does not provide all the pathological information needed to interpret a treatment study or plan.[5]

Risk factors do not determine an individual outcome

The NHS describes increasing age, family history, inherited variants and Black African or African Caribbean background as relevant risk factors. Those are population-level observations, not a diagnosis or an inevitable outcome. Worry about risk can be discussed even without symptoms.[1]

PSA is useful but not cancer-specific

NHS explains that a higher PSA can occur with benign enlargement or prostate inflammation as well as cancer. Early prostate cancer often causes no symptoms, while urinary problems may have noncancerous causes. A result or symptom pattern cannot reliably settle the diagnosis on its own.[2]

MRI and biopsy have different jobs

The inspected NHS pathway describes specialist MRI to assess the prostate and help decide whether further testing is needed. A biopsy obtains tissue for examination. Further imaging after diagnosis can assess spread. An MRI result is not automatically a complete pathological diagnosis, and the exact pathway can differ across health systems.[3]

Grade and stage are related but distinct

Gleason scoring and Grade Group describe microscopic tumor characteristics. Stage includes extent, with PSA and grade informing the classification. A Grade Group number is not a stage number.[4]

Surveillance and watchful waiting have different aims

NCI distinguishes active surveillance, which defers immediate treatment while retaining possible curative treatment if progression appears, from watchful waiting focused on symptom relief when needed. Studies do not always distinguish the labels consistently. Neither means abandoning follow-up, and eligibility depends on cancer features, health and preferences.[5]

An asymptomatic screening recommendation is not a diagnostic rule

The inspected 2018 USPSTF statement recommends an individual PSA-screening decision for men aged 55 to 69 and recommends against routine PSA screening from age 70. It concerns people without symptoms or a previous diagnosis. It does not say that new symptoms should be ignored because someone is outside a screening age range.[7]

Its assessment weighs a small potential reduction in prostate-cancer deaths against false positives, biopsy harms, overdiagnosis and treatment harms. This older dated framework does not establish every current risk-adapted approach. A screening decision should retain the source, date, population and outcome rather than being reduced to “PSA good” or “PSA bad.”[7]

Treatment purposes and harms deserve separate discussion

NHS describes surgery, radiotherapy and hormone therapy, with other systemic treatments in appropriate settings. Removing the prostate can affect urinary control, erections, ejaculation and fertility; these are separate outcomes. Radiation and medicines have their own adverse effects. Hormone therapy can slow disease without being a stand-alone cure.[6]

Useful consultation questions include the aim of treatment, the likely absolute benefit, monitoring requirements, effects on sexual and urinary function, and which options remain if the cancer changes. A technique being available does not establish superior long-term benefit for every patient.[6]

Evidence & uncertainty

Monitoring can be appropriate for selected cancers, but it is not universally interchangeable with treatment. In a long-term randomized trial, cancer deaths were uncommon across groups while metastases were more frequent with active monitoring. The outcome and the population both matter.[8]

Selected-source overview · Independent review pending

Published questions

Does an elevated PSA result establish prostate cancer?

Selected-source overview · Independent review pending. Read the evidence context.

Benign enlargement and inflammation can also raise PSA.[2]

Evidence behind this answer

Symptoms of prostate cancer
agency condition or prevention explanation · 2025
Selected relevant original official page passages inspected · Symptoms, noncancerous alternatives and PSA limitations